-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer announced today that the U.S. Food and Drug Administration (FDA) has accepted a new drug application (sNDA) for LORBRENA ® as a first-line treatment for ALC-positive metastasis non-small cell lung cancer (NSCLC).
approval of the SNDA is based on data from key CROWN studies.
In fact, it has been previously reported that the new generation of lung cancer target drug Loratini: significantly improved progression-free survival of ALC-positive NSCLC patients LORBRENA is a third-generation ALC inhibitor specifically developed to inhibit the most common tumor mutations, these mutations drive resistance to current drugs, up to 40% of ALC-positive lung cancer patients have brain metastasis.
Detailed results see: NEJM: "Head-to-head" Phase III study confirmed the treatment of ALK-positive non-small cell lung cancer, Laroteni significantly better than cytocinic non-small cell lung cancer (NSCLC) is still one of the highest mortality malignant tumors in humans, NSCLC in order of morbidity for adenocarcinoma, squamous cancer, large cell carcinoma and non-specific types.
For most NSCLC patients, the current first-line treatment is platinum-based combination chemotherapy or the use of molecularly targeted drugs for specific populations, although most patients after pre-induced treatment can significantly improve clinical symptoms and quality of life, but most patients will relapse within the next year, a one-year survival rate of only 30%-50%.
。
